Cites del registre
Cita APA (7th ed.)
ATM, L., & SI, O. (2024). LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Dove Medical Press.
Copiat
No s'ha pogut copiar
Cita Chicago (17th ed.)
ATM, Lee, i Ou SI. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Dove Medical Press, 2024.
Copiat
No s'ha pogut copiar
Cita MLA (9th ed.)
ATM, Lee, i Ou SI. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Dove Medical Press, 2024.
Copiat
No s'ha pogut copiar
Atenció: Aquestes cites poden no estar 100% correctes.